You just read:

Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation

News provided by

Correvio Pharma Corp

Jun 24, 2019, 07:00 ET